BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 9740973)

  • 1. Prostate-specific antigen utilization in Ontario: extent of testing in patients with and without cancer.
    Bunting PS; Chong N; Holowaty EJ; Goel V
    Clin Biochem; 1998 Aug; 31(6):501-11. PubMed ID: 9740973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen testing in Ontario: reasons for testing patients without diagnosed prostate cancer.
    Bunting PS; Goel V; Williams JI; Iscoe NA
    CMAJ; 1999 Jan; 160(1):70-5. PubMed ID: 9934349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer.
    Stenman UH; Hakama M; Knekt P; Aromaa A; Teppo L; Leinonen J
    Lancet; 1994 Dec; 344(8937):1594-8. PubMed ID: 7527116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis.
    Tawfik A
    Ont Health Technol Assess Ser; 2015; 15(11):1-37. PubMed ID: 26366237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Annual PSA tests are not necessary for men with a PSA level below 2 ng/mL: findings of the Imari prostate cancer screening program.
    Uozumi J; Tokuda Y; Fujiyama C; Takagi N; Meiri H; Kuratomi K; Nakamura K; Ichigi Y; Yoshinaga H; Kinoshita N; Masaki Z
    Int J Urol; 2002 Jun; 9(6):334-9. PubMed ID: 12110098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Practice of early detection of prostate cancer : Descriptive survey in preparation for the PSAInForm study].
    Simbrich A; Semjonow A; Donner-Banzhoff N; Hense HW
    Urologe A; 2018 Jun; 57(6):702-708. PubMed ID: 29671079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination.
    Schröder FH; Roobol-Bouts M; Vis AN; van der Kwast T; Kranse R
    Urology; 2001 Jan; 57(1):83-90. PubMed ID: 11164149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Use of prostate-specific antigen testing].
    Mukai TO; Bro F; Pedersen KV; Vedsted P
    Ugeskr Laeger; 2010 Mar; 172(9):696-700. PubMed ID: 20199746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening program of prostate cancer at Tokai University Hospital: characterization of prostate-specific antigen measurement.
    Tokunaga M; Yasuda M; Miyakita H; Kawamura Y; Shoji S; Sasaki H; Kono T; Kobayashi Y; Shima M; Usui Y; Masuda A; Kinoshita H; Ogawa T; Honma Y; Osamura RY; Terachi T
    Tokai J Exp Clin Med; 2005 Jul; 30(2):103-10. PubMed ID: 16146200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brief report: Free prostate-specific antigen test utilization. Consistency with guidelines.
    Jackson BR; Roberts WL
    J Gen Intern Med; 2005 Sep; 20(9):859-61. PubMed ID: 16117757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen testing practices and outcomes.
    Hoffman RM; Blume P; Gilliland F
    J Gen Intern Med; 1998 Feb; 13(2):106-10. PubMed ID: 9502370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prostate-specific antigen test.
    Roobol MJ
    Expert Opin Med Diagn; 2013 Sep; 7(5):423-6. PubMed ID: 23875974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testing and referral patterns in the years surrounding the US Preventive Services Task Force recommendation against prostate-specific antigen screening.
    Hutchinson R; Akhtar A; Haridas J; Bhat D; Roehrborn C; Lotan Y
    Cancer; 2016 Dec; 122(24):3785-3793. PubMed ID: 27658175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
    Otto SJ; van der Cruijsen IW; Liem MK; Korfage IJ; Lous JJ; Schröder FH; de Koning HJ
    Int J Cancer; 2003 Jun; 105(3):394-9. PubMed ID: 12704675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The digital rectal exam, prostate-specific antigen and transrectal echography in the diagnosis of prostatic cancer].
    Martínez de Hurtado J; Chéchile Toniolo G; Villavicencio Mavrich H
    Arch Esp Urol; 1995 Apr; 48(3):247-59. PubMed ID: 7538749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PSA-use in a Spanish industrial area.
    Páez A; Luján M; Llanes L; Romero I; de la Cal MA; Miravalles E; Berenguer A
    Eur Urol; 2002 Feb; 41(2):162-6. PubMed ID: 12074403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-Specific Antigen Testing Initiation and Shared Decision-Making: Findings from the 2000 and 2015 National Health Interview Surveys.
    Li J; Ding H; Richards TB; Martin I; Kobrin S; Marcus PM
    J Am Board Fam Med; 2018; 31(4):658-662. PubMed ID: 29986994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.